
The FDA approved cannabidiol (CBD) last year for the treatment of seizures associated with Lennox-Gastaut and Dravet syndromes in patients aged 2 years and older. As pharmacists, we will likely be called upon as experts in CBD therapeutics.
Dr. Jeff Fudin graduated from Albany College of Pharmacy & Health Sciences with a BS and PharmD. He is a Diplomate to the Academy of Integrative Pain Management, a Fellow to ACCP, ASHP, & FSMB, a member of several other professional organizations. He is CEO of Remitigate (remitigate.com), an opioid safety software development LLC. Dr. Fudin is a section editor for Pain Medicine & Co_Editor-A-Large for Practical Pain Management. He practices as a clinical pharmacy specialist (WOC) and director of PGY-2 pharmacy pain residency programs at the Stratton Veterans Administration Medical Center in Albany, New York and has academic affiliations with Western New England University and Albany Colleges of Pharmacy.
The FDA approved cannabidiol (CBD) last year for the treatment of seizures associated with Lennox-Gastaut and Dravet syndromes in patients aged 2 years and older. As pharmacists, we will likely be called upon as experts in CBD therapeutics.
Emgality (Galcanezumab-gnlm) is a self-administered once monthly subcutaneous injection and the third in its class for the preventative treatment of migraine in adults.
Millions worldwide dread the onset of debilitating migraines. There is a new drug class on the horizon that is thought to put a stop to the root of migraines.
Despite a decline in the rate of opioid prescribing, the CDC reports that the number of opioid related deaths continues to rise. The pharmacology and pharmacokinetics of prescription and illicit fentanyl could help to shed light on why the opioid epidemic has taken the path that it has.
Opioid allergies are often misdiagnosed. Improper allergy diagnosis may lead to delays in treatment and unnecessary drug avoidance.
A look at the different receptor bindings that affect analgesic effect.
The established therapeutic dosing for gabapentin in neuropathic pain is 1800-3600 mg/day in 3 divided doses in patients with normal renal function.
Here is how to distinguish between those who need prescriptions to manage pain and those seeking controlled substances for illicit reasons.
This testing has a positive clinical and therapeutic impact on dosage requirements and ethical considerations.
Published: August 24th 2017 | Updated:
Published: October 18th 2017 | Updated:
Published: December 20th 2017 | Updated:
Published: January 6th 2018 | Updated:
Published: March 6th 2018 | Updated:
Published: October 29th 2018 | Updated: